This review found that delaying the initiation of adjuvant chemotherapy for more than eight weeks after surgery significantly decreased overall survival, but not relapse-free survival. The conclusions were supported by the data, but should be interpreted with caution due to the unclear validity of the included studies.
Authors' objectives
To assess the effect on survival of delaying adjuvant chemotherapy in patients with colorectal cancer.
Searching
PubMed was searched to August 2009; search terms were reported. Abstracts from relevant conference proceedings were screened and references were crosschecked. The review was restricted to studies published either as abstracts or full text papers.
Study selection
Studies that assessed the effects of shorter or longer delay to chemotherapy on overall survival and relapse free survival in patients with stage II/III colon or rectal cancer were eligible for inclusion.
Median age, where reported, ranged from 57 to 74 years. Included patients had stage II and III colon and rectal tumours. For delayed treatment, the delay was eight weeks in most studies; three studies had delays of four to six weeks. Various chemotherapy protocols were administered, the most common was 5-FU based.
It appeared that multiple authors selected studies for inclusion, but exact details were unclear.
Assessment of study quality
The authors did not formally assess study quality.
Data extraction
Data were extracted to calculate relative risks (RRs) or hazard ratios (HR) together with 95% confidence intervals (CIs). Relative risks were calculated such that a value of more than one indicated worse survival in patients with longer delay.
It appeared that multiple authors extracted data, but exact details were unclear.
Methods of synthesis
Summary relative risks were estimated using the Mantel-Haenszel fixed-effect model. It appeared that heterogeneity was assessed, but exact details were lacking.
Results of the review
Fourteen studies were included (n=17,645 participants). Study designs included post hoc stratifications of randomised controlled trials (RCTs), cohorts and retrospective studies. Three studies did not report sufficient data for statistical analysis and so were excluded from the meta-analysis. Six studies were available only as abstracts. Follow-up duration was not reported.
Eight studies assessed a cut-off for delay of eight weeks. These studies found that delayed adjuvant chemotherapy was associated with worse overall survival (RR 1.20, 95% CI 1.15 to 1.26). Only two studies reported on relapse-free survival; results for this outcome were not presented.
